PDCD1 and sarcoma: Additionally, axitinib in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody for advanced sarcoma patients, demonstrated that 28% of patients achieved SD and 25% showed partial response (ClinicalTrials.gov, number NCT02636725) (Wilky et al., 2019).